{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:26:14Z","timestamp":1792513574271,"version":"4.5.0"},"reference-count":9,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:00:00Z","timestamp":1609372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Limited evidence is available regarding low (24\/26 mg) and middle (49\/51 mg) doses of sacubitril\/valsartan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The purpose of this study was to investigate the effect of sacubitril\/valsartan dose on heart failure (HF) hospitalization and mortality in patients with HF with reduced ejection fraction (HFrEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective multicenter cohort study compared 3 doses of sacubitril\/valsartan in patients with HFrEF. The coprimary outcomes were all-cause mortality and rehospitalization for HF. Propensity matching analysis was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 721 eligible patients, propensity matching created a cohort with an effective sample size of 652 (24\/26-mg group [n = 326], 49\/51-mg group [n = 147], 97\/103-mg group [n = 179]). The HF hospitalization rates were 29.14% in the 24\/26-mg group, 19.51% in the 49\/51-mg group, and 16.10% in the 97\/103-mg group (24\/26 vs 49\/51 mg: HR = 1.56, 95% CI = 1.04-2.34; 24\/26 vs 97\/103 mg: HR = 1.79, 95% CI = 1.18-2.73; 49\/51 vs 97\/103 mg: HR = 1.15, 95% CI = 0.70-1.89). All-cause mortality rates were 29.63% in the 24\/26-mg group, 17.58% in the 49\/51-mg group, and 9.27% in the 97\/103-mg group (24\/26 vs 49\/51 mg: HR = 1.67, 95% CI = 1.07-2.59; 24\/26 vs 97\/103 mg: HR = 2.56, 95% CI = 1.54-4.24; 49\/51 vs 97\/103 mg: HR = 1.54, 95% CI = 0.84-2.82).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Relevance<\/jats:title>\n                    <jats:p>Sacubitril\/valsartan 97\/103- or 49\/51-mg dose is associated with a lower mortality or hospitalization rate for HF in patients receiving sacubitril\/valsartan compared with the 24\/26-mg dose group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1060028020983522","type":"journal-article","created":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T02:02:16Z","timestamp":1609466536000},"page":"1069-1075","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Evaluating Sacubitril\/Valsartan Dose Dependence on Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3393-8025","authenticated-orcid":false,"given":"Kazuhiko","family":"Kido","sequence":"first","affiliation":[{"name":"West Virginia University School of Pharmacy, Morgantown, WV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Bianco","sequence":"additional","affiliation":[{"name":"West Virginia University School of Medicine, Morgantown, WV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8534-0474","authenticated-orcid":false,"given":"Marco","family":"Caccamo","sequence":"additional","affiliation":[{"name":"West Virginia University School of Medicine, Morgantown, WV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fang","sequence":"additional","affiliation":[{"name":"West Virginia Clinical and Translational Science Institute, Morgantown, WV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sokos","sequence":"additional","affiliation":[{"name":"West Virginia University School of Medicine, Morgantown, WV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,12,31]]},"reference":[{"key":"bibr1-1060028020983522","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.04.025"},{"key":"bibr2-1060028020983522","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"bibr3-1060028020983522","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.580"},{"key":"bibr4-1060028020983522","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851"},{"key":"bibr5-1060028020983522","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.04.070"},{"key":"bibr6-1060028020983522","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2019.03.010"},{"key":"bibr7-1060028020983522","doi-asserted-by":"publisher","DOI":"10.1007\/s00059-018-4690-6"},{"key":"bibr8-1060028020983522","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.100.23.2312"},{"key":"bibr9-1060028020983522","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61913-9"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020983522","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020983522","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020983522","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:16:05Z","timestamp":1777374965000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020983522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1177\/1060028020983522"],"URL":"https:\/\/doi.org\/10.1177\/1060028020983522","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,31]]}}}